Tehran University of Medical Sciences

Science Communicator Platform

Faculty Members have conducted research related to the Correction To: Impact of 2017 Acc/Aha Guideline on Prevalence, Awareness, Treatment, Control, and Determinants of Hypertension: A Population-Based Cross-Sectional Study in Southwest of Iran (Population Health Metrics, (2021), 19, 1, (26), 10.1186/S12963-021-00260-5)
Mehrzad Mirzania

Associate Professor of Hematology & Oncology

Department Internal Medicine

School of Medicine

Vali Asr Hospital

Tehran University of Medical Sciences

All Documents
1. Efficacy of Ac-T Versus Tac Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer: A Retrospective Analysis, International Journal of Breast Cancer (2026)
2. The Role of Locoregional Treatment in Non-Progressive De Novo Metastatic Breast Cancer Under Systemic Treatment: A Randomized Controlled Trial (Ltmbc), Annals of Surgical Oncology (2026)
3. “Colorectal Cancer Care Quality in a Developing Country: Insights From a Comparison of Teaching and Non-Teaching Hospitals in Iran”, PLOS ONE (2025)
4. Neoadjuvant Chemotherapy in Patients With Her2-Negative Breast Cancer: A Report From Clinical Breast Cancer Registry of Iran, Archives of Iranian medicine (2024)
5. Syringic Acid Attenuates Oxidative Stress in Plasma and Peripheral Blood Mononuclear Cells of Patients With Acute Myeloid Leukemia, Nutrition and Cancer (2023)
6. A Randomized, Double-Blind, Phase Iii, Non-Inferiority Clinical Trial Comparing the Efficacy and Safety of Ta4415v (A Proposed Trastuzumab Biosimilar) and Herceptin (Trastuzumab Reference Product) in Her2-Positive Early-Stage Breast Cancer Patients, BMC Pharmacology and Toxicology (2022)
7. Comparing Efficacy and Safety of P013, a Proposed Pertuzumab Biosimilar, With the Reference Product in Her2-Positive Breast Cancer Patients: A Randomized, Phase Iii, Equivalency Clinical Trial, BMC Cancer (2022)
8. Comparing Efficacy and Safety of P013, a Proposed Pertuzumab Biosimilar, With the Reference Product in Her2-Positive Breast Cancer Patients: A Randomized, Phase Iii, Equivalency Clinical Trial, BMC Cancer (2022)
9. Correction: Comparing Efficacy and Safety of P013, a Proposed Pertuzumab Biosimilar, With the Reference Product in Her2-Positive Breast Cancer Patients: A Randomized, Phase Iii, Equivalency Clinical Trial (Bmc Cancer, (2022), 22, 1, (960), 10.1186/S12885-022-09895-5), BMC Cancer (2022)
10. Correction: Comparing Efficacy and Safety of P013, a Proposed Pertuzumab Biosimilar, With the Reference Product in Her2-Positive Breast Cancer Patients: A Randomized, Phase Iii, Equivalency Clinical Trial (Bmc Cancer, (2022), 22, 1, (960), 10.1186/S12885-022-09895-5), BMC Cancer (2022)
11. Post-Marketing Surveillance of a Generic Oxaliplatin (Alvoxalⓡ) in Iranian Patients With Cancer, Current Therapeutic Research - Clinical and Experimental (2022)
12. Evaluation of Pathologic Complete Response (Pcr) to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients With Estrogen Receptor Positive and Her2 Negative and Impact of Predicting Variables on Pcr, European Journal of Breast Health (2020)
13. Modifications in Breast Cancer Guidelines in Covid-19 Pandemic; an Iranian Consensus, Archives of Breast Cancer (2020)
14. Assessment of Carvedilol Therapy in Prevention of Heart Failure in Her2 Positive Breast Cancer Patients Receiving Trastuzumab, Acta Medica Iranica (2019)
15. A Survey of Infection in Allogenic Hematopoietic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia, International Journal of Organ Transplantation Medicine (2018)
16. Efficacy and Safety of Celecoxib Monotherapy for Mild to Moderate Depression in Patients With Colorectal Cancer: A Randomized Double-Blind, Placebo Controlled Trial, Psychiatry Research (2017)
17. Estimation of the Prevalence and Direct Medical Costs of Chronic Myeloid Leukemia in the I.R. of Iran in the Era of Tyrosine Kinase Inhibitors, Asia-Pacific Journal of Clinical Oncology (2017)
18. Travel Burden for Cancer Patients in Iran: Analysis of 1700 Patients From the Cancer Institute of Iran, Archives of Iranian Medicine (2017)
19. Treatment Outcomes and Clinicopathologic Characteristics of Triple-Negative Breast Cancer: A Report From Cancer Institute of Iran, International Journal of Hematology-Oncology and Stem Cell Research (2017)
20. A Patient With Multiple Myeloma and Renal Cell Carcinoma, International Journal of Hematology-Oncology and Stem Cell Research (2016)
21. Approach to the Triple Negative Breast Cancer in New Drugs Area, International Journal of Hematology-Oncology and Stem Cell Research (2016)
22. Attitude of Iranian Medical Oncologists Toward Economic Aspects, and Policy-Making in Relation to New Cancer Drugs, International Journal of Health Policy and Management (2016)
23. Preliminary Results of Allogenic Hematopoietic Stem Cell Transplantation of Non-M3 Acute Myeloid Leukemia, Iranian Journal of Blood and Cancer (2016)
24. Self-Reported Versus Proxy Reported Quality of Life for Breast Cancer Patients in the Islamic Republic of Iran; [Qualite De Vie Auto-Evaluee Et Evaluee Par Un Tiers Pour Des Patients Atteints D’Un Cancer Du Sein En Republique Islamique D’Iran], Eastern Mediterranean Health Journal (2016)
25. Effect of Silymarin Administration on Cisplatin Nephrotoxicity: Report From a Pilot, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial, Phytotherapy Research (2015)
26. Hepatic Iron Overload and Fibrosis in Patients With Beta Thalassemia Major After Hematopoietic Stem Cell Transplantation: A Pilot Study, International Journal of Hematology-Oncology and Stem Cell Research (2015)
27. Medical Oncology, History and Its Future in Iran, Archives of Iranian Medicine (2015)
28. Medical Oncology, History and Its Future in Iran, Archives of Iranian Medicine (2015)
29. Urine Ratio of Neutrophil Gelatinase-Associated Lipocalin to Creatinine As a Marker for Early Detection of Cisplatinassociated Nephrotoxicity, Iranian Journal of Kidney Diseases (2015)